Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.

Currency in GBP	2025
Operating Income	-155.3 Million
Income Before Tax	-139.9 Million
Income Tax Expense	5.30 Million
Net Income	-145.2 Million
Eps	-0.15
Epsdiluted	-0.15
Weighted Average Shs Out	960.99 Million
Weighted Average Shs Out Dil	960.99 Million
Depreciation And Amortization	49.80 Million
Interest Expense	2.80 Million
Ebit	-137.1 Million
Interest Income	11.80 Million
Net Interest Income	9.00 Million
Period	FY
Ebitda	-105.5 Million
Net Cash Provided By Operating Activities	N/A
Source	yahoo

Oxford Nanopore Technologies plc Annual Reports (10-K)